Page 22 - Alkermes News Today

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Viatris (VTRS – Research Report), with a price t...

Gracefields development by Glenveagh sits off M6 on the outskirts of vibrant Weatmeath town

Wilmington, Delaware, United States, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The addiction treatment market was estimated to have acquired US$ 6.39 billion in 2020. It is anticipated to

Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six brokerages that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month […]

A recent examination of Vivitrol’s clinical trial data uncovered many hidden overdoses. Its preferential use in the criminal justice system must stop

Here are the speakers and sessions most highly anticipated by veteran DPE attendees.

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of multiple posters highlighting real-world and clinical data at the 36th Annual...

Hood River Capital Management LLC grew its position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 6.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 731,630 shares of the company’s stock after acquiring an additional 45,688 shares during the quarter. […]

13D Management LLC trimmed its holdings in Alkermes plc (NASDAQ:ALKS – Free Report) by 28.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 276,084 shares of the company’s stock after selling 107,500 shares during the period. Alkermes accounts for […]

Alkermes Announces Launch of 6th Annual Alkermes Pathways Research ...